Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-001 vs Augmentin ES-600 PK in Pediatric Bacterial Infection
NCT05584683Phase 1Completed
- Sponsor
- Kaizen Bioscience
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of LP-001 in bacterial infection (2 arms), sponsored by Kaizen Bioscience. Primary endpoints: Mean plasma concentration-time curves of amoxicillin and clavulanic acid, Area under the serum concentration-time curve (AUC) of amoxicillin and clavulanic acid combination and 1 more. Started Aug 2023; status: completed.
02
Drugs
LP-001
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT05584683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05584683.